Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26490219 | 0.88 | MAOB (0.47) | LMNASMN1; SMN2RAB9AALDH1A1KMT2A | |
| SCHEMBL26491210 | 0.85 | CA12 (0.36) | SMN1; SMN2RAB9AHPGDALDH1A1 | |
| SCHEMBL8260541 | 0.82 | MAOB (0.37) | GAAKMT2A | |
| SCHEMBL5281557 | 0.79 | LMNA (0.50) | GAALMNASMN1; SMN2RAB9AHPGD | |
| SCHEMBL5279338 | 0.79 | GAA (0.41) | GAALMNASMN1; SMN2RAB9AHPGD | |
| SCHEMBL26490250 | 0.78 | ESR1 (0.41) | HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL5282172 | 0.78 | LMNA (0.49) | GAALMNASMN1; SMN2RAB9AHPGD | |
| SCHEMBL6038107 | 0.77 | MAOB (0.43) | GAALMNASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL26490999 | 0.77 | PREP (0.38) | LMNASMN1; SMN2RAB9AALDH1A1KMT2A | |
| SCHEMBL6037951 | 0.77 | HPGD (0.50) | GAALMNASMN1; SMN2RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | GAA 569/4885LMNA 851/4885SMN1; SMN2 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.